Exforge

How to order Exforge

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Exforge on Prescriptsy

Exforge is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Exforge is a prescription-only combination medicine containing amlodipine and valsartan, two widely used antihypertensive agents prescribed together for the treatment of essential hypertension (high blood pressure) in adults.

Amlodipine is a calcium channel blocker that relaxes arterial smooth muscle, while valsartan is an angiotensin II receptor blocker (ARB) that prevents the hormone angiotensin II from causing blood vessel constriction.

This dual mechanism provides more effective blood pressure reduction than either medicine used alone.

Exforge is manufactured by Novartis and is available as a prescription-only medicine (POM) in the United Kingdom.

Hypertension affects approximately one in three adults in England and is the single largest modifiable risk factor for cardiovascular disease, stroke, heart failure, and chronic kidney disease.

Despite the availability of effective treatments, many patients do not achieve adequate blood pressure control on a single antihypertensive medicine.

Current UK guidelines from NICE (guideline NG136) recommend combination therapy as a standard approach when monotherapy is insufficient, recognising that combining drugs with complementary mechanisms improves efficacy while minimising dose-dependent side effects.

This page provides a detailed clinical guide to Exforge, covering how it works, the evidence supporting its use, dosing, side effects, safety information, and how to obtain a prescription in the United Kingdom.

Important safety information about Exforge

Before reading further, note the following critical safety points.

• Exforge is contraindicated in pregnancy. ARBs can cause serious foetal harm including renal failure, skull defects, and death. Stop Exforge immediately if pregnancy is confirmed and contact your GP.
• Do not take Exforge with aliskiren if you have diabetes or significant kidney impairment.
• Do not combine Exforge with an ACE inhibitor (dual renin-angiotensin blockade is harmful).
• Tell your prescriber about all other medicines you take, particularly NSAIDs, diuretics, potassium supplements, and lithium.
• Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Understanding hypertension and why combination therapy matters

Blood pressure is maintained by the interaction of cardiac output (how much blood the heart pumps) and peripheral vascular resistance (how tight or relaxed the blood vessels are).

Multiple physiological systems regulate these factors, including the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and local vascular tone regulated by calcium signalling.

Because these systems operate in parallel and compensate for each other, blocking a single pathway with monotherapy often produces an incomplete blood pressure response.

The remaining systems increase their activity to maintain blood pressure, a phenomenon known as counter-regulation.

Combination therapy with agents targeting different pathways overcomes counter-regulation by simultaneously reducing vascular tone through calcium channel blockade (amlodipine) and inhibiting the RAAS (valsartan).

This is why NICE NG136 recommends an ARB or ACE inhibitor combined with a calcium channel blocker as first-line combination therapy for most hypertensive patients.

Large outcome trials, including VALUE and ASCOT, have demonstrated that effective blood pressure reduction with combination therapy significantly reduces the risk of stroke, myocardial infarction, and cardiovascular death.

How Exforge works: dual mechanism of action

Amlodipine: calcium channel blockade

Amlodipine is a long-acting dihydropyridine calcium channel blocker.

It selectively inhibits L-type voltage-gated calcium channels in vascular smooth muscle cells, preventing the influx of extracellular calcium required for muscle contraction.

This produces relaxation of arteriolar smooth muscle and reduces systemic vascular resistance.

Amlodipine has a slow onset of action (peak effect at 6 to 12 hours) and an exceptionally long plasma half-life (approximately 35 to 50 hours), which provides smooth 24-hour blood pressure control with once-daily dosing and forgives occasional missed doses.

Amlodipine has no clinically significant effect on heart rate or cardiac conduction at therapeutic doses.

Valsartan: angiotensin II receptor blockade

Valsartan is a selective, competitive antagonist of the angiotensin II type 1 (AT1) receptor.

Angiotensin II is the primary effector peptide of the RAAS and exerts potent vasoconstrictive, sodium-retaining, and aldosterone-stimulating effects through AT1 receptor activation.

By blocking AT1 receptors, valsartan prevents these actions, leading to vasodilation, reduced aldosterone secretion, mild natriuresis, and decreased sympathetic nervous system activation.

Unlike ACE inhibitors, ARBs do not affect bradykinin metabolism, which accounts for their lower incidence of dry cough.

Valsartan also provides renal protective effects by reducing intraglomerular pressure, making it particularly beneficial for patients with early diabetic nephropathy or proteinuria.

Synergy and complementary tolerability

The combination of amlodipine and valsartan produces additive blood pressure reduction because the two agents target independent pathways.

Additionally, the combination mitigates side effects seen with each component alone.

Amlodipine-induced peripheral oedema (caused by precapillary arteriolar vasodilation increasing capillary hydrostatic pressure) is partially offset by the post-capillary venodilation produced by valsartan, which reduces venous pressure.

Clinical trials have shown that the incidence of peripheral oedema with the amlodipine/valsartan combination is significantly lower than with amlodipine monotherapy at the same dose.

Similarly, the reflex sympathetic activation triggered by amlodipine is dampened by the sympatholytic properties of RAAS blockade with valsartan.

Clinical evidence for Exforge

The efficacy of the amlodipine/valsartan combination has been demonstrated in multiple large clinical trials.

The EX-FAST study showed that switching patients uncontrolled on monotherapy to amlodipine/valsartan achieved blood pressure targets in approximately 75% of patients within 16 weeks.

The EX-EFFeCTS trial demonstrated superior blood pressure reduction compared with amlodipine monotherapy and valsartan monotherapy individually.

The combination has been shown to reduce both systolic and diastolic blood pressure by an additional 5 to 10 mmHg compared with either component alone, which translates into meaningful cardiovascular risk reduction.

Long-term outcome data from studies using the individual components (ALLHAT for amlodipine, VALUE for valsartan) support the cardiovascular protective effects of both agents.

While no dedicated cardiovascular outcomes trial has been conducted specifically for the fixed-dose combination, the extensive evidence base for each component, combined with the well-established principle that blood pressure reduction is the primary driver of cardiovascular benefit, supports the clinical value of Exforge.

UK prescribing guidelines and NICE recommendations

NICE guideline NG136 (Hypertension in adults: diagnosis and management) provides the framework for antihypertensive treatment in the UK.

For adults aged under 55 without type 2 diabetes, first-line monotherapy is an ACE inhibitor or ARB.

For adults aged 55 and over, or Black patients of African or Caribbean origin at any age, first-line monotherapy is a calcium channel blocker.

When monotherapy does not achieve target blood pressure, the recommended step 2 combination is an ACE inhibitor or ARB with a calcium channel blocker.

Exforge, as a fixed-dose combination of valsartan (ARB) and amlodipine (CCB), aligns with this NICE-recommended step 2 approach.

The British National Formulary (BNF) lists amlodipine/valsartan combinations and provides dosing guidance.

GPs and hospital physicians routinely prescribe this combination, either as the branded product Exforge or as generic amlodipine plus valsartan given separately.

Fixed-dose combinations offer the practical advantage of reducing pill burden, which has been shown to improve adherence in hypertension management.

Blood pressure targets in the UK

NICE recommends the following blood pressure targets: below 140/90 mmHg for clinic measurements in most adults, below 135/85 mmHg for ambulatory or home readings.

For adults aged 80 and over, the clinic target is below 150/90 mmHg.

More intensive targets may be considered in certain high-risk patients, for example those with established cardiovascular disease or chronic kidney disease with proteinuria, following individualised clinical assessment.

Dosage and administration of Exforge

Exforge tablets are taken once daily, with or without food, at the same time each day.

The available strengths are: amlodipine 5 mg/valsartan 80 mg, amlodipine 5 mg/valsartan 160 mg, and amlodipine 10 mg/valsartan 160 mg.

The appropriate strength depends on the patient's current treatment and blood pressure response.

Patients already taking amlodipine and valsartan as separate tablets can be switched directly to the equivalent Exforge combination.

Patients not adequately controlled on monotherapy typically start on 5 mg/80 mg and the dose is titrated upward as needed at 2-weekly intervals.

The maximum recommended dose is 10 mg/160 mg once daily.

No dose adjustment is necessary for mild to moderate renal impairment.

Exforge is not recommended for patients with severe renal impairment (GFR below 30 mL/min) or those on dialysis.

In mild to moderate hepatic impairment, the valsartan dose should not exceed 80 mg. Exforge is contraindicated in severe hepatic impairment.

No dose adjustment is required in elderly patients, though cautious initiation is advised.

Side effects of Exforge

Common side effects

Peripheral oedema (swelling of ankles and lower legs), headache, nasopharyngitis, influenza-like symptoms, flushing, dizziness, and fatigue are the most commonly reported adverse effects.

Peripheral oedema related to amlodipine is dose-dependent and occurs less frequently with the combination than with amlodipine monotherapy.

Dizziness may indicate excessive blood pressure reduction, particularly in the first few days of treatment or after dose increases.

Uncommon and rare side effects

Uncommon effects include palpitations, postural hypotension, abdominal pain, nausea, constipation, rash, myalgia (muscle pain), arthralgia (joint pain), and back pain.

Gingival hyperplasia (gum overgrowth) may occur with prolonged amlodipine use and resolves after stopping the drug or switching to an alternative.

Elevated liver enzymes, hyperkalaemia, and elevated serum creatinine have been reported, particularly in patients with pre-existing renal or hepatic conditions.

Rare effects include angioedema (less common with ARBs than ACE inhibitors), severe skin reactions, and hepatitis. Any episode of facial or throat swelling requires immediate discontinuation and emergency medical assessment.

When to seek urgent medical advice

Contact your GP or NHS 111 if you experience persistent dizziness, ankle swelling that worsens progressively, palpitations, or symptoms suggesting very low blood pressure (feeling faint on standing).

Seek emergency care (call 999 or attend A&E) if you develop swelling of the face, lips, tongue, or throat, difficulty breathing, chest pain, or signs of severe allergic reaction.

Report any suspected adverse reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings, precautions, and drug interactions

Pregnancy and breastfeeding

Exforge is strictly contraindicated in pregnancy. ARBs can cause oligohydramnios, foetal renal impairment, skull ossification defects, and neonatal death. Women of childbearing potential must use effective contraception throughout treatment. Breastfeeding is not recommended during Exforge therapy.

Dual RAAS blockade

Do not use Exforge together with an ACE inhibitor or aliskiren (particularly in patients with diabetes or renal impairment). Dual blockade of the RAAS increases the risk of severe hypotension, acute kidney injury, and hyperkalaemia without additional cardiovascular benefit.

Renal and hepatic impairment

Renal function and potassium levels should be monitored before and during treatment, particularly in patients with pre-existing kidney disease, diabetes, or concomitant use of other medicines affecting kidney function. Exforge is contraindicated in severe hepatic impairment and severe renal impairment.

Volume depletion

Patients who are volume-depleted (for example, those taking high-dose diuretics, those with reduced oral fluid intake, or those with diarrhoea or vomiting) are at increased risk of symptomatic first-dose hypotension.

Correct volume depletion before starting Exforge or initiate at the lowest available dose with close monitoring.

Drug interactions

NSAIDs (including ibuprofen, naproxen, and selective COX-2 inhibitors) may reduce the blood pressure-lowering effect of valsartan and increase the risk of renal impairment.

Lithium levels may rise during concurrent ARB therapy; monitor lithium concentrations closely. CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavir, grapefruit juice) may increase amlodipine plasma levels.

Simvastatin doses should not exceed 20 mg daily when used alongside amlodipine due to increased myopathy risk.

Potassium-sparing diuretics and potassium supplements should be used with caution alongside the valsartan component.

How to get Exforge in the UK

Exforge is available on NHS prescription from your GP or hospital specialist.

It is typically prescribed when combination therapy with a calcium channel blocker and ARB is indicated, either as step 2 therapy following inadequate response to monotherapy or as initial combination therapy in patients with significantly elevated blood pressure.

An authorised online prescriber registered with the GPhC can also prescribe Exforge following a clinical consultation and review of current blood pressure readings and medical history.

The NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Lifestyle measures alongside Exforge

Medication is one component of blood pressure management.

NICE recommends lifestyle modifications for all hypertensive patients, including regular physical activity (at least 150 minutes of moderate-intensity exercise per week), dietary salt reduction (target below 6 g per day), maintaining a healthy body weight, limiting alcohol intake (no more than 14 units per week), eating a diet rich in fruit, vegetables, and whole grains, and managing stress.

Smoking cessation is essential for overall cardiovascular risk reduction. These measures complement the blood pressure-lowering effects of Exforge and reduce overall cardiovascular risk.

When to seek medical advice

Contact your GP or NHS 111 if you experience persistent or worsening side effects, if your home blood pressure readings are consistently above target, or if you develop new symptoms.

Attend regular blood pressure reviews as recommended by your GP.

Seek emergency care if you experience chest pain, sudden severe headache, sudden weakness or numbness on one side of the body, difficulty speaking, or visual disturbance, as these may indicate a cardiovascular emergency.

Sources

• Exforge Film-coated Tablets, Summary of Product Characteristics (EMC)
• Amlodipine, British National Formulary (BNF)
• Valsartan, British National Formulary (BNF)
• NICE NG136: Hypertension in adults: diagnosis and management
• High blood pressure (hypertension), NHS
• MHRA Yellow Card Scheme